EMMA (Emmaus Life Sciences) Short-Term Debt: $28.24 Mil (As of Mar. 2026)


What is Emmaus Life Sciences Short-Term Debt?

Emmaus Life Sciences EMMA +0.01% Short-Term Debt is $28.24 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's Short-Term Debt for the quarter that ended in Mar. 2026 was $28.24 Mil.

Emmaus Life Sciences's quarterly Short-Term Debt increased from Sep. 2025 ($27.58 Mil) to Dec. 2025 ($28.53 Mil) but then declined from Dec. 2025 ($28.53 Mil) to Mar. 2026 ($28.24 Mil).

Emmaus Life Sciences's annual Short-Term Debt declined from Dec. 2023 ($27.72 Mil) to Dec. 2024 ($27.48 Mil) but then increased from Dec. 2024 ($27.48 Mil) to Dec. 2025 ($28.53 Mil).

Emmaus Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Emmaus Life Sciences Short-Term Debt Related Terms

Emmaus Life Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Short-Term Debt Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.76 23.84 27.72 27.48 28.53

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.51 28.20 27.58 28.53 28.24
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $28.24 Mil mean?
Emmaus Life Sciences (EMMA) has a Short-Term Debt of $28.24 Mil as of Mar. 2026.
Is Emmaus Life Sciences' Short-Term Debt too high?
Emmaus Life Sciences' current Short-Term Debt is $28.24 Mil.
How does Emmaus Life Sciences' Short-Term Debt compare to PTIX and BZYR?
Emmaus Life Sciences' Short-Term Debt of $28.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Emmaus Life Sciences's current Short-Term Debt is $28.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14.2% above its estimated fair value. The current Short-Term Debt is $28.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Short-Term Debt is $28.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.